CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 1,040 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 1,040 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total transaction of $51,230.40. Following the completion of the transaction, the general counsel owned 95,857 shares in the company, valued at $4,721,915.82. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CRISPR Therapeutics Trading Up 2.6%

Shares of CRISPR Therapeutics stock traded up $1.30 on Thursday, hitting $51.52. 1,352,731 shares of the company’s stock traded hands, compared to its average volume of 1,748,176. The firm’s 50-day moving average price is $55.08 and its two-hundred day moving average price is $53.20. The stock has a market capitalization of $4.98 billion, a PE ratio of -10.82 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $75.06. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $10.18 million during the quarter. On average, research analysts expect that CRISPR Therapeutics AG will post -4.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. AdvisorNet Financial Inc boosted its position in CRISPR Therapeutics by 25.5% during the 3rd quarter. AdvisorNet Financial Inc now owns 10,673 shares of the company’s stock worth $590,000 after acquiring an additional 2,170 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of CRISPR Therapeutics by 92.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after acquiring an additional 597 shares in the last quarter. Green Alpha Advisors LLC grew its stake in shares of CRISPR Therapeutics by 1.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company’s stock worth $3,141,000 after acquiring an additional 982 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of CRISPR Therapeutics by 43.6% in the third quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company’s stock valued at $632,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Congress Asset Management Co. raised its holdings in shares of CRISPR Therapeutics by 1.6% in the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after purchasing an additional 1,777 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on CRSP shares. Citizens Jmp reiterated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Monday, August 31st. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.